A common haplotype in NAPEPLD is associated with severe obesity in a Norwegian population-based cohort (the HUNT study)

Obesity

Volumn 19, Issue 3, 2011, Pages 612-617

  Wangensteen, Teresia ^a,b   Akselsen, Hanne ^a   Holmen, Jostein ^c   Undlien, Dag ^a,b   Retterstøl, Lars ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 18;

ADULT; AGED; ARTICLE; BODY MASS; CNR1 GENE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; GENE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; LIPF GENE; MAJOR CLINICAL STUDY; MALE; NAPEPLD GENE; OBESITY; POPULATION RESEARCH; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; STEAP4 GENE; WAIST CIRCUMFERENCE;

EID: 79952005795     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2010.219     Document Type: Article

References (40)

1. Maes HH, Neale MC, Eaves LJ. Genetic and environmental factors in relative body weight and human adiposity. Behav Genet 1997;27:325-351. (Pubitemid 27415169)
2. Willer CJ, Speliotes EK, Loos RJ et al. Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat Genet 2009;41:25-34.
3. Matias I, Di Marzo V. Endocannabinoids and the control of energy balance. Trends Endocrinol Metab 2007;18:27-37. (Pubitemid 44960014)
4. Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 2008;7:438-455. (Pubitemid 351649182)
5. Fu J, Kim J, Oveisi F, Astarita G, Piomelli D. Targeted enhancement of oleoylethanolamide production in proximal small intestine induces across-meal satiety in rats. Am J Physiol Regul Integr Comp Physiol 2008;295:R45-R50.
6. Armand M. Lipases and lipolysis in the human digestive tract: where do we stand? Curr Opin Clin Nutr Metab Care 2007;10:156-164. (Pubitemid 46220307)
7. Drew BS, Dixon AF, Dixon JB. Obesity management: update on orlistat. Vasc Health Risk Manag 2007;3:817-821.
8. Sommer G, Garten A, Petzold S et al. Visfatin/PBEF/Nampt: structure, regulation and potential function of a novel adipokine. Clin Sci 2008;115:13-23. (Pubitemid 351930789)
9. Wellen KE, Fucho R, Gregor MF et al. Coordinated regulation of nutrient and inflammatory responses by STAMP2 is essential for metabolic homeostasis. Cell 2007;129:537-548. (Pubitemid 46660973)
10. Arner P, Stenson BM, Dungner E et al. Expression of six-transmembrane protein of prostate 2 in human adipose tissue associates with adiposity and insulin resistance. J Clin Endocrinol Metab 2008;93:2249-2254. (Pubitemid 351831543)
11. Netea MG, Joosten LA, Lewis E et al. Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance. Nat Med 2006;12:650-656. (Pubitemid 43865233)
12. Holmen J, Midthjell K, Kruger O, et al. The Nord-Trøndelag Health Study 1995-97 (HUNT2): objectives, contents, methods and participation. Norw J Epidemiol 2003;13:19-32.
13. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-265. (Pubitemid 40202029)
14. Purcell S, Cherny SS, Sham PC. Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 2003;19:149-150. (Pubitemid 36150192)
15. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68:978-989. (Pubitemid 32289743)
16. Stephens M, Scheet P. Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am J Hum Genet 2005;76:449-462. (Pubitemid 40250525)
17. Dudbridge F. Likelihood-based association analysis for nuclear families and unrelated subjects with missing genotype data. Hum Hered 2008;66:87-98. (Pubitemid 351482562)
18. Li SS, Cheng JJ, Zhao LP. Empirical vs. Bayesian approach for estimating haplotypes from genotypes of unrelated individuals. BMC Genet 2007;8:2.
19. Di Marzo V, Després JP. CB1 antagonists for obesity-what lessons have we learned from rimonabant? Nat Rev Endocrinol 2009;5:633-638.
20. Viveros MP, de Fonseca FR, Bermudez-Silva FJ, McPartland JM. Critical role of the endocannabinoid system in the regulation of food intake and energy metabolism, with phylogenetic, developmental, and pathophysiological implications. Endocr Metab Immune Disord Drug Targets 2008;8:220-230.
21. Williams CM, Kirkham TC. Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 1999;143:315-317. (Pubitemid 29204987)
22. Schwartz GJ, Fu J, Astarita G et al. The lipid messenger OEA links dietary fat intake to satiety. Cell Metab 2008;8:281-288.
23. O'Sullivan SE. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br J Pharmacol 2007;152:576-582. (Pubitemid 350034977)
24. O'Rahilly S, Farooqi IS. Human obesity as a heritable disorder of the central control of energy balance. Int J Obes (Lond) 2008;32(Suppl 7):S55-S61.
25. Le Foll B, Forget B, Aubin HJ, Goldberg SR. Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies. Addict Biol 2008;13:239-252. (Pubitemid 351692986)
26. Cohen C, Perrault G, Voltz C, Steinberg R, Soubrié P. SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol 2002;13:451-463. (Pubitemid 35178842)
27. Peeters A, Beckers S, Mertens I, Van Hul W, Van Gaal L. The G1422A variant of the cannabinoid receptor gene (CNR1) is associated with abdominal adiposity in obese men. Endocrine 2007;31:138-141. (Pubitemid 350195147)
28. Russo P, Strazzullo P, Cappuccio FP et al. Genetic variations at the endocannabinoid type 1 receptor gene (CNR1) are associated with obesity phenotypes in men. J Clin Endocrinol Metab 2007;92:2382-2386. (Pubitemid 46997151)
29. Bordicchia M, Battistoni I, Mancinelli L et al. Cannabinoid CB1 receptor expression in relation to visceral adipose depots, endocannabinoid levels, microvascular damage, and the presence of the Cnr1 A3813G variant in humans. Metab Clin Exp 2010;59:734-741.
30. Müller TD, Reichwald K, Wermter AK et al. No evidence for an involvement of variants in the cannabinoid receptor gene (CNR1) in obesity in German children and adolescents. Mol Genet Metab 2007;90:429-434. (Pubitemid 46484433)
31. Benzinou M, Chèvre JC, Ward KJ et al. Endocannabinoid receptor 1 gene variations increase risk for obesity and modulate body mass index in European populations. Hum Mol Genet 2008;17:1916-1921. (Pubitemid 351865840)
32. Ruaño G, Windemuth A, Kocherla M et al. Physiogenomic analysis of weight loss induced by dietary carbohydrate restriction. Nutr Metab (Lond) 2006;3:20.
33. Bailey SD, Loredo-Osti JC, Lepage P et al. Common polymorphisms in the promoter of the visfatin gene (PBEF1) influence plasma insulin levels in a French-Canadian population. Diabetes 2006;55:2896-2902. (Pubitemid 44923693)
34. Böttcher Y, Teupser D, Enigk B et al. Genetic variation in the visfatin gene (PBEF1) and its relation to glucose metabolism and fat-depot-specific messenger ribonucleic acid expression in humans. J Clin Endocrinol Metab 2006;91:2725-2731. (Pubitemid 44024644)
35. Zhang YY, Gottardo L, Thompson R et al. A visfatin promoter polymorphism is associated with low-grade inflammation and type 2 diabetes. Obesity (Silver Spring) 2006;14:2119-2126. (Pubitemid 46121965)
36. Blakemore AI, Meyre D, Delplanque J et al. A rare variant in the visfatin gene (NAMPT/PBEF1) is associated with protection from obesity. Obesity (Silver Spring) 2009;17:1549-1553.
37. Miot A, Maimaitiming S, Emery N et al. Genetic variability at the six-transmembrane protein of prostate 2 locus and the metabolic syndrome: the data from an epidemiological study on the Insulin Resistance Syndrome (DESIR) study. J Clin Endocrinol Metab 2010;95:2942-2947.
38. Evans J, Collins M, Jennings C et al. The association of interleukin-18 genotype and serum levels with metabolic risk factors for cardiovascular disease. Eur J Endocrinol 2007;157:633-640. (Pubitemid 350187380)
39. Tiret L, Godefroy T, Lubos E et al. Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease. Circulation 2005;112:643-650. (Pubitemid 41099042)
40. Thompson SR, Sanders J, Stephens JW, Miller GJ, Humphries SE. A common interleukin 18 haplotype is associated with higher body mass index in subjects with diabetes and coronary heart disease. Metab Clin Exp 2007;56:662-669. (Pubitemid 46574729)